Response (N = 34)
| Time point . | Overall response . | CR . | Partial response . | Progressive disease . | Not evaluable* . |
|---|---|---|---|---|---|
| Monotherapy lead-in | 34 (100; 89.7-100) | 18 (52.9; 35.1-70.2) | 16 (47.1; 29.8-64.9) | 0 (0; 0-10.3) | 0 (0; 0-10.3) |
| Cycle 2 | 33 (97.1; 84.7-99.9) | 33 (97.1; 84.7-99.9) | 0 (0; 0-10.3) | 0 (0; 0-10.3) | 1 (2.9; 0.1-15.3) |
| End of treatment | 31 (91.2; 76.3-98.1) | 31 (91.2; 76.3-98.1) | 0 (0; 0-10.3) | 1 (2.9; 0.1-15.3) | 2 (5.9; 0.7-19.7) |
| Time point . | Overall response . | CR . | Partial response . | Progressive disease . | Not evaluable* . |
|---|---|---|---|---|---|
| Monotherapy lead-in | 34 (100; 89.7-100) | 18 (52.9; 35.1-70.2) | 16 (47.1; 29.8-64.9) | 0 (0; 0-10.3) | 0 (0; 0-10.3) |
| Cycle 2 | 33 (97.1; 84.7-99.9) | 33 (97.1; 84.7-99.9) | 0 (0; 0-10.3) | 0 (0; 0-10.3) | 1 (2.9; 0.1-15.3) |
| End of treatment | 31 (91.2; 76.3-98.1) | 31 (91.2; 76.3-98.1) | 0 (0; 0-10.3) | 1 (2.9; 0.1-15.3) | 2 (5.9; 0.7-19.7) |
Data are presented as n (%; 95% CI).
Reasons for nonevaluable were 1 subject with grade 5 toxicity during cycle 1 of brentuximab-AVD, and 1 subject removed from study due to hypersensitivity reactions.